Denmark's Novo Nordisk launched a rival bid for US obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the fast-growing and competitive weight-loss drug market.

Novo Nordisk bid up to $8.5 billion, inclu

📰

Continue Reading on India Today

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →